Xenon Pharmaceuticals – $34.5 Million Follow-⁠On

San Diego – September 16, 2016 – Cooley advised the underwriters on Xenon Pharmaceuticals’ $34.5 million follow-on offering of 4,600,000 common shares. 

Xenon, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own, and for larger market indications that it intends to partner with global pharmaceutical companies.

Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering.

Cooley previously advised the underwriters on Xenon’s IPO

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Charlie Kim Partner, San Diego
Drew Williamson Partner, San Francisco
David Peinsipp Partner, San Francisco
Jonie Kondracki Partner, San Francisco
Kristin VanderPas Partner, San Francisco
Denny Won Associate, San Francisco
Natasha Leskovsek Partner, Washington, DC
Bill Christiansen Partner, Seattle
Susan Cooper Philpot Retired Partner, San Francisco
James C. Kitch Senior Counsel, Palo Alto